News

Remembering Professor Robert Stirling OAM

Memorial tribute graphic featuring Professor Robert Stirling OAM speaking at a TOGA conference. The image includes the heading "Remembering Prof Robert Stirling OAM" and the words "A respected clinician, leader, educator and innovator whose vision has improved lung cancer care across Australia and around the world." The design uses a subdued blue colour palette to honour his legacy.

Professor Robert Stirling OAM BSc (Hons), MB BCh (Hons), MRCPI, FRACP, RCPI, MPH devoted his career to improving the lives of people with lung cancer through clinical excellence, research, education and compassionate leadership.

Professor Robert Stirling OAM leaves an enduring legacy through his leadership, research and unwavering commitment to improving lung cancer care in Australia.

A Leader in Lung Cancer Care

For more than two decades, Rob combined outstanding clinical care with a determination to improve the health system around it. As a Consultant Respiratory Physician at Alfred Health and Epworth Hospital, he championed multidisciplinary care and helped establish The Alfred’s lung cancer multidisciplinary meeting as a model of collaborative practice.

Transforming Quality Improvement

Rob recognised that improving outcomes required more than excellent clinicians. It required measurement.

As founding Chair of the Victorian Lung Cancer Registry, he helped create one of Australia’s most influential clinical quality registries, enabling hospitals to benchmark care and drive continuous improvement. He later co-founded the Lung Cancer Clinical Quality Data Platform, extending this work nationally.

A Voice Shaping National Policy

Beyond the clinic, Rob influenced lung cancer care across Australia. He advised Cancer Australia, contributed to guidance for earlier recognition of lung cancer symptoms, supported the Australian Lung Cancer Screening Program and represented Australia on international quality initiatives through IASLC and ICHOM.

Prof Robert Stirling OAM speaking into a microphone at a lung cancer conference

An Educator and Mentor

Rob was equally passionate about developing the next generation of clinicians. Over many years he supervised medical students, respiratory physicians and researchers at Monash University and Alfred Health, earning a reputation as a generous mentor and respected teacher.

Recognising an Extraordinary Contribution

In 2026, Rob was appointed a Member of the Order of Australia in recognition of his significant service to respiratory oncology, research and education. Earlier this year, TOGA was proud to award him Honorary Membership in acknowledgement of his remarkable contribution to thoracic cancer care.

A Lasting Legacy

Professor Stirling’s influence extends far beyond the roles he held. His legacy lives on through the clinicians he mentored, the quality initiatives he established and the countless patients whose care has been improved because of his vision.

On behalf of the Board, members and staff of the Thoracic Oncology Group of Australasia, we extend our sincere condolences to Rob’s family, friends and colleagues.

 
Prof Robert Stirling OAM and Mrs Lisa Briggs talking in a relaxed dinner environment

Share this

Facebook
Twitter
LinkedIn
Learn what a KRAS G12C mutation means, how targeted therapies work, and how Australian clinical trials are testing new lung cancer treatments.
The PHARAOH-A trial will evaluate savolitinib plus osimertinib in MET-positive amplified or overexpressed EGFR-mutated lung cancer after progression on prior TKI and chemotherapy.
New evidence is changing the way surgeons approach early-stage lung cancer, with lung-sparing surgery becoming an option for carefully selected patients.
Everything you need to know about the Australia-wide trial using liquid biopsy to guide treatment after targeted therapy progression in advanced lung cancer
The DEFIANT trial will evaluate datopotamab deruxtecan (Dato-DXd) in EGFR exon 20 insertion NSCLC after targeted therapy and chemotherapy.
Discover the major advances from TOGA ASM 2026, including lung cancer screening, precision medicine, immunotherapy, survivorship and multidisciplinary care shaping the future of thoracic oncology.
Their work is often invisible, but its impact isn't. Specialist Lung Cancer Nurses are quietly becoming the backbone of modern lung cancer care.
Teletrials, also known as digi trials, are when a clinician at a primary site uses telehealth (videoconference or telephone calls) to enrol, consent, treat and/or
A simple guide to what happens after a lung CT scan in the Australian National Lung Cancer Screening Program
Updates from our Inspirational Research Grant 2025 recipients on pioneering lung microbiome research and its impact on immunotherapy efficacy.
Clinicians, nurses, consumers and health service leaders came together at TOGA’s Lung Cancer Optimal Care Pathway workshop to examine why Australia continues to struggle to
Understanding the language helps patients, families and clinicians stay informed, confident and part of the conversation.
TOGA is pleased to announce the latest appoints for our Scientific Committee.
Discover how a vibrant Lunar New Year Banquet, organised by Dr. Angeline Low and Ms. Maria Chan, raised over $50,000 for vital lung cancer research.
The MRFF is holding $1B+ in unspent funds. Learn why TOGA is calling for the release of this research funding to accelerate lung cancer breakthroughs
Discover TOGA’s FY25 highlights, including the new Strategic Plan, clinical trial milestones and record membership growth across Australia and New Zealand.
The Preventative and Quality Care Working Group represents TOGA’s commitment to improving the outcomes of thoracic cancers.
TOGA’s Working Groups are evolving to better reflect where thoracic cancer research is heading: From prevention and early detection through to advanced disease and living
Learn how to turn your endorsed research concept into a clinical trial; from sponsor selection to budgeting, data, safety and protocol design.
Learn how to design an investigator-initiated clinical trial, from refining your research idea to securing TOGA endorsement and funding.
Learn why EGFR-positive lung cancer disproportionately affects Asian populations and non-smokers. Discover modern targeted therapies and symptoms to watch for.
Discover how 2025 transformed lung cancer care in Australia. Explore the impact of national screening, modern diagnostics, and new PBS treatment approvals.
Let's take a moment to celebrate the incredible guests, ground breaking discussions, and dedicated listeners that made 2025 our most successful year yet.
If you are interested in joining TOGA on a Committee, please submit your nominations by 30 January 2026
The final Scientific Meeting of 2025 was held in November. Five concepts were presented, spanning both Recurrent and Metastatic NSCLC populations and four Mesothelioma concepts.
Bispecific antibodies target two pathways at once, reshaping lung cancer treatment through dual checkpoint blockade and targeted precision.
Research advances only improve outcomes when they are accessible to patients. TOGA drives change in lung cancer care by advocating through stakeholder submissions, including PBS.......
We are excited about awarding new grants but first, we check in on progress made by our 2024 recipients....
Learn how TOGA’s ASPiRATION study led to Medicare-funded genomic testing for lung cancer and national best practice guidelines in Australia.
Optimise cancer care for older Adults with practical tips and tools to implement person-centred geriatric oncology.
DYNAMALK is a significant clinical trial investigating the potential of comprehensive genomic profiling to revolutionise the treatment of ALK+ Non-Small Cell Lung Cancer (NSCLC)
Liquid biopsy is revolutionising lung cancer care by using a blood test to examine the tumour without the need for a lung biopsy.
OCEANiC will determine if patients with resected stage II to IIIA EGFR mutant NSCLC require intensification of osimertinib monotherapy with chemotherapy.
Latest results from the SHERLOCK clinical trial show promising first-line outcomes for patients with KRAS G12C-mutated lung cancer, combining sotorasib with chemotherapy and bevacizumab.
A re-cap of the Scientific Committee meeting in August 2025 and the year to date.
Celebrating TOGA's leadership transition: We honour the service of our past Board members and welcome the new Chair and Directors who will chart TOGA’s future.